Covered recipient · General Payments record
ROBERT THAIN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$8,864.02
- Reported across 641 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $291.16 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $128.83 | 7 |
| Amgen Inc. | $38.40 | 2 |
| PFIZER INC. | $36.33 | 2 |
| Abbott Laboratories | $22.33 | 1 |
| Tris Pharma Inc | $18.22 | 1 |
| Novo Nordisk AS | $17.57 | 1 |
| Astellas Pharma US Inc | $16.08 | 1 |
| Acerta Pharma LLC | $13.40 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.33 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124958979 | CMS |
| Amgen Inc. | $19.18 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117699514 | CMS |
| Amgen Inc. | $19.22 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117699516 | CMS |
| Astellas Pharma US Inc | $16.08 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139361595 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.40 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104541922 | CMS |
| Lilly USA, LLC | $14.06 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135380206 | CMS |
| Lilly USA, LLC | $18.80 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135355190 | CMS |
| Lilly USA, LLC | $19.30 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135367686 | CMS |
| Lilly USA, LLC | $16.39 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135392139 | CMS |
| Lilly USA, LLC | $22.55 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135380208 | CMS |
| Lilly USA, LLC | $18.61 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135359078 | CMS |
| Lilly USA, LLC | $19.12 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135392811 | CMS |
| Novo Nordisk Inc | $17.57 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096727652 | CMS |
| PFIZER INC. | $22.55 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132020325 | CMS |
| PFIZER INC. | $13.78 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131408524 | CMS |
| Tris Pharma Inc | $18.22 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147236639 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.